Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NsGene AS

www.nsgene.com

Latest From NsGene AS

Another R&D Deal For Takeda As It Inks Parkinson’s Alliance

Deals and R&D partnerships are coming thick and fast for Takeda in the first few days of the year, with the major Japanese firm unveiling a new tie-up with NsGene to progress direct-delivered cell therapies for Parkinson's disease.

BioPharmaceutical Japan

Biogen Idec buys analgesic developer Convergence for $200m+

Biogen Idec has agreed to pay $200m up front and up to $475m in milestones to acquire the UK developer of drugs for neuropathic pain Convergence Pharmaceuticals. The target company's most promising pipeline drug is CNV1014802, which has yielded positive Phase II results for trigeminal neuralgia (TGN), an orphan condition characterized by excruciating face pain.

Neurology Immune Disorders

Deals Shaping the Medical Industry (09/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Favourable safety of NsGene's encapsulated cells in Alzheimer's

A safety review of the first three Alzheimer's disease patients given NsGene's nerve-growth-factor secreting encapsulated cells has been favourable, and a further three patients have now be included in the Phase Ib clinical trial.

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • NsGene AS
  • Senior Management
  • Teit E Johansen, PhD, Pres. & CEO
    Lars U Wahlberg, MD, PhD, EVP, COO
  • Contact Info
  • NsGene AS
    Phone: (45) 4460 8900
    Baltorpvej 154
    Ballerup, DK-2750
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register